跳轉至內容
Merck
全部照片(1)

重要文件

616452

Sigma-Aldrich

RepSox

≥95% (HPLC), solid, TGF-β RI kinase inhibitor, Calbiochem

同義詞:

TGF-β RI激酶抑制剂II, ALK5抑制剂II,转化生长因子-βI型受体激酶抑制剂II,2-(3-(6-甲基吡啶-2-基)-1H-吡唑-4-基)-1,5-萘啶

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H13N5
CAS號碼:
分子量::
287.32
MDL號碼:
分類程式碼代碼:
51111800
NACRES:
NA.77
暫時無法取得訂價和供貨情況

產品名稱

TGF-β RI激酶抑制剂II, TGF-β RI Kinase Inhibitor II, CAS 446859-33-2, is a cell-permeable, potent, reversible, ATP-competitive inhibitor of TGF-β R1 kinase (IC₅₀ = 23 nM and 4 nM for ALK5 binding & auto-phosphorylation).

品質等級

化驗

≥95% (HPLC)

形狀

solid

效力

23 nM IC50

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

顏色

yellow

溶解度

DMSO: 5 mg/mL
methanol: 5 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

SMILES 字串

[nH]1ncc(c1c4nc(ccc4)C)c2nc3c(nccc3)cc2

InChI

1S/C17H13N5/c1-11-4-2-5-16(20-11)17-12(10-19-22-17)13-7-8-14-15(21-13)6-3-9-18-14/h2-10H,1H3,(H,19,22)

InChI 密鑰

LBPKYPYHDKKRFS-UHFFFAOYSA-N

一般說明

一种细胞渗透性萘啶基吡唑化合物,可作为TGF-βⅠ型受体的有效、选择性、可逆和ATP竞争性抑制剂(ALK5;ALK5结合、ALK5自动磷酸化和HepG2细胞中TGF-β细胞分析的IC50分别为23 nM、4 nM和18 nM)。对9种密切相关的激酶的影响最小,包括IC50 >16 µM的p38 MAPK。也可作为50 mM的DMSO溶液(目录号508158)提供。

生化/生理作用

主靶
ALKS结合
产物与ATP竞争。
次级靶标
ALK 5自身磷酸化(IC₅₀= 4 nM)
细胞可渗透性:是

包裝

用惰性气体包装

警告

毒性:标准处理(A)

重構

复溶后,等分并冷冻保存(-20°C)。贮备溶液在-20°C下可稳定保存至多6个月。

其他說明

Gellibert, F., et al. 2004.J. Med. Chem.47, 4494.
Ichida, J. K., et al. 2009.Cell Stem Cell 5, 491.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Satoru Shinriki et al.
The Journal of pathology, 244(3), 367-379 (2017-12-14)
Oral squamous cell carcinoma (OSCC) has a very poor prognosis because of its highly invasive nature, and the 5-year survival rate has not changed appreciably for the past 30 years. Although cylindromatosis (CYLD), a deubiquitinating enzyme, is thought to be a
Sayaka Imatsuji et al.
Oncology research, 32(1), 139-150 (2024-01-08)
Growing evidence suggests an association between epithelial-mesenchymal transition (EMT), a hallmark of tumor malignancy, and chemoresistance to a number of anti-cancer drugs. However, the mechanism of EMT induction in the process of acquiring anti-cancer drug resistance remains unclear. To address
Ayumi Kanemaru et al.
Cancer cell international, 22(1), 358-358 (2022-11-16)
Tumor suppressor CYLD dysfunction by loss of its expression, triggers malignant transformation, especially drug resistance and tumor invasion/metastasis. Although loss of CYLD expression is significantly associated with poor prognosis in a large variety of tumors, no clinically-effective treatment for CYLD-negative
Nicolas Wieder et al.
Cell metabolism, 35(5), 887-905 (2023-04-20)
Cellular exposure to free fatty acids (FFAs) is implicated in the pathogenesis of obesity-associated diseases. However, there are no scalable approaches to comprehensively assess the diverse FFAs circulating in human plasma. Furthermore, assessing how FFA-mediated processes interact with genetic risk
Nina Sofi Funa et al.
Stem cell reports, 19(7), 973-992 (2024-06-29)
Genetic differences between pluripotent stem cell lines cause variable activity of extracellular signaling pathways, limiting reproducibility of directed differentiation protocols. Here we used human embryonic stem cells (hESCs) to interrogate how exogenous factors modulate endogenous signaling events during specification of

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務